Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Chief Financial Officer | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-10-05 | Direct | 200,000 |
Reported balance
After 2026-10-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 200,000 · Balance 200,000 F1: This option will vest as to 1/4 of the total award on the first anniversary of October 5, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2030-10-05 | Direct | 200,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 200,000 · Balance 200,000 F2: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F3: The RSUs will vest as to 1/4 of the total award on each of October 5, 2027, October 5, 2028, October 5, 2029 and October 5, 2030 subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest as to 1/4 of the total award on the first anniversary of October 5, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.
F3: The RSUs will vest as to 1/4 of the total award on each of October 5, 2027, October 5, 2028, October 5, 2029 and October 5, 2030 subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 705,410 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 477,191 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. F4: Includes 2,581 shares recently acquired in Esperion's Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2034-03-14 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 200,000 · Balance 0 F5: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-03-14 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 213,000 · Balance 0 F5: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2036-03-13 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-13 · Disposition to issuer · Disposed 221,270 · Balance 0 F5: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 477,191 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: Includes 2,581 shares recently acquired in Esperion's Employee Stock Purchase Plan.
F5: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:15 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantRestricted Stock Unit (RSU) · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001953943-26-000004 · form4-10062026_081008.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-10-05 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F3 · derivative.exercise_date: The RSUs will vest as to 1/4 of the total award on each of October 5, 2027, October 5, 2028, October 5, 2029 and October 5, 2030 subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:15 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001953943-26-000004 · form4-10062026_081008.xml · derivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-10-05 F1 · derivative.exercise_date: This option will vest as to 1/4 of the total award on the first anniversary of October 5, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 221,270 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001628280-26-048000 · wk-form4_1783973020.xml · derivative · entry 4 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 221,270 shares Expires 2036-03-13 F5 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F5 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 213,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-048000 · wk-form4_1783973020.xml · derivative · entry 3 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 213,000 shares Expires 2035-03-14 F5 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F5 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001628280-26-048000 · wk-form4_1783973020.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2034-03-14 F5 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F5 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerCommon Stock | 705,410 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-048000 · wk-form4_1783973020.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2 · shares: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · shares: Includes 477,191 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. F4 · shares: Includes 2,581 shares recently acquired in Esperion's Employee Stock Purchase Plan. F2 · price: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · price: Includes 477,191 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 10,773 | $3.16 | $33,988.82 |
DisclosureSEC source: 0001628280-26-044264 · wk-form4_1781813149.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,829 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:12 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 6,424 | $2.71 | $17,376.92 |
DisclosureSEC source: 0001628280-26-019409 · wk-form4_1773864769.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 713,602 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 20:19 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 221,270 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001628280-26-018186 · wk-form4_1773692366.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,270 Underlying: Common Stock · 221,270 shares Expires 2036-03-13 F1 · derivative.exercise_date: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 20:19 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 247,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-018186 · wk-form4_1773692366.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,026 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026. F2 · balance_after: Includes 5,071 shares recently acquired in Esperion's Employee Stock Purchase Plan. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:09 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 7,337 | $3.67 | $26,904.78 |
DisclosureSEC source: 0001628280-25-057942 · wk-form4_1766092168.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,525 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| September 17, 2025 Filed Sep 18, 2025 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 7,046 | $2.81 | $19,785.17 |
DisclosureSEC source: 0001953943-25-000004 · wk-form4_1758225965.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,862 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. F2 · balance_after: Includes 7,446 shares recently acquired in Esperion's Employee Stock Purchase Plan. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 11 | $1.12 | $12.27 |
DisclosureSEC source: 0001628280-25-035334 · wk-form4_1752869115.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,462 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 22:44 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 7,229 | $1.15 | $8,327.81 |
DisclosureSEC source: 0001628280-25-032217 · wk-form4_1750286660.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,473 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 8 | $0.96 | $7.71 |
DisclosureSEC source: 0001628280-25-018566 · wk-form4_1745265814.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,702 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 20:03 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 3,535 | $1.48 | $5,242.41 |
DisclosureSEC source: 0001628280-25-013812 · wk-form4_1742414592.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,710 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:16 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 213,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001628280-25-013198 · wk-form4_1742246208.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2035-03-14 F1 · derivative.exercise_date: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be in June 15, 2025. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:16 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 238,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-013198 · wk-form4_1742246208.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,245 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be in June 15, 2025. F2 · balance_after: Includes 6,574 shares recently acquired in Esperion's Employee Stock Purchase Plan. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:50 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 11 | $1.86 | $20.46 |
DisclosureSEC source: 0001628280-25-006801 · wk-form4_1740088204.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,671 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 21:38 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 9 | $2.27 | $20.39 |
DisclosureSEC source: 0001628280-25-002037 · wk-form4_1737495531.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,682 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 21:14 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 3,245 | $2.42 | $7,865.88 |
DisclosureSEC source: 0001628280-24-051875 · wk-form4_1734556476.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,691 F1 · shares: Shares were sold to satisfy tax obligation on vested shares of restricted stock units. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:32 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001628280-24-011488 · wk-form4_1710534711.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-03-14 F1 · derivative.exercise_date: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2024. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 20:32 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011488 · wk-form4_1710534711.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,936 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2024. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 13:21 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001628280-23-007968 · wf-form4_167888646953394.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2033-03-14 F3 · derivative.exercise_date: Such options will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 13:21 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-007968 · wf-form4_167888646953394.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,936 F1 · shares: Such award will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service. F2 · balance_after: Consists of 73,936 shares of common stock held, including 2,306 shares recently acquired in Esperion's Employee Stock Purchase Plan. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:07 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001104659-22-126269 · tm2232259-1_4seq1.xml · derivative · entry 2 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2032-12-09 F2 · derivative.exercise_date: Such options will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of December 15, 2022 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:07 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-126269 · tm2232259-1_4seq1.xml · nonDerivative · entry 1 Halladay Benjamin · CIK 0001953943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,771 F1 · shares: Such award will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of December 15, 2022 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.